Drug Trial Radar · NCT00628589
Staccato Loxapine in Agitated Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
344
Actual
Start
Feb 2008
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Alexza Pharmaceuticals, Inc.Not stated
- Sponsor type
- Not stated
- First posted
- Mar 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients
Conditions
- Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mgDrug
Inhaled loxapine 5 mg
Inhaled loxapine 10 mgDrug
Inhaled loxapine 10 mg
Inhaled placeboDrug
Inhaled placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in PANSS-EC From BaselineTime frame: Baseline and 2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atlanta Center for Medical Research
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.